TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33581721

Group type: EXPERIMENTAL
Intervention: ANI-guided group (loading dose of 75 μg of fentanyl followed by 25 μg when ANI score was under 50)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (same loading dose followed by 25 μg every 30 min with additional doses for inadequate analgesia)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ANI-guided group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 34592491

Group type: EXPERIMENTAL
Intervention: Storytelling method (n=40)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lecture method (n=30)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 70
Study: 32967413

Group type: EXPERIMENTAL
Intervention: Subcapsular anesthesia (SA)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Pericapsular anesthesia (PA)
Number of subjects: 323
Study: 32269181

Group type: EXPERIMENTAL
Intervention: 0.066 mg/kg/day GH
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.033 mg/kg/day GH
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 32160171

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 34077291

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 0
Study: 33081476

Group type: EXPERIMENTAL
Intervention: Modified rubber band ligation (MRBL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Milligan‐Morgan haemorrhoidectomy (MMH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both MRBL and MMH
Number of subjects: 120
Study: 35679212

Group type: EXPERIMENTAL
Intervention: Trauma exposure (direct, witnessed, and indirect)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Multivariate regression models for posttraumatic stress and anxiety
Number of subjects: 87
Study: 34933316

Group type: EXPERIMENTAL
Intervention: Chlorhexidine in 70% alcohol
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Povidone-iodine in 70% alcohol
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Povidone-iodine in aqueous solution
Number of subjects: 482
Study: 32990206

Group type: EXPERIMENTAL
Intervention: Propofol monotherapy
Number of subjects: 277

Group type: COMPARATOR
Intervention: Combination sedation (propofol with midazolam, fentanyl, dexmedetomidine, and/or ketamine)
Number of subjects: 277
Study: 35108470

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 970

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 970
Study: 34156534

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting
Number of subjects: 20
Study: 35690060

Group type: EXPERIMENTAL
Intervention: e‐cigarettes with 30 mg/g nicotine in e‐liquid
Number of subjects: 23

Group type: COMPARATOR
Intervention: conventional cigarettes
Number of subjects: 23
Study: 34039736

Group type: EXPERIMENTAL
Intervention: 22‐gage Tuohy needle
Number of subjects: 204

Group type: COMPARATOR
Intervention: 22‐gage Quincke needle
Number of subjects: 204
Study: 33070517

Group type: EXPERIMENTAL
Intervention: Active stimulation (10 Hz repetitive transcranial magnetic stimulation delivered to the left dorsolateral prefrontal cortex at 80% of the resting motor threshold)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active stimulation (10 Hz repetitive transcranial magnetic stimulation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 27
Study: 36063821

Group type: EXPERIMENTAL
Intervention: Asundexian 10 mg
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Asundexian 20 mg
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg
Number of subjects: 1808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1808
Study: 33872982

Group type: EXPERIMENTAL
Intervention: Prolgolimab 1 mg/kg every 2 weeks (arm 1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Prolgolimab 3 mg/kg every 3 weeks (arm 2)
Number of subjects: 126
Study: 32429063

Group type: EXPERIMENTAL
Intervention: NVP‐1703
Number of subjects: 95
Study: 34480657

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33403448

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group A), chewed for 30 min every 8 hours starting 6 hours post-operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No chewing gum (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group A)
Number of subjects: 100
Study: 35803640

Group type: EXPERIMENTAL
Intervention: Self-assessment questionnaires (MADRS-S, GAD-7, KEDS)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Perception of own poor work ability
Number of subjects: 341
Study: 34588237

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (first dose)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MVA‐BN‐Filo (second dose)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (booster dose)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (first dose) to Ad26.ZEBOV (booster dose)
Number of subjects: 700
Study: 36428044

Group type: EXPERIMENTAL
Intervention: Solution-focused approach (7-session program of anger management and prevention of violent behavior)
Number of subjects: 48
Study: 34110392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: COMPARATOR
Intervention: Active comparators
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Double-blinded trials
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Clinical outcomes as primary efficacy endpoint
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: At least 2 pivotal trials for supplemental approvals
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: At least 2 pivotal trials for original approvals
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Trial duration of 12 months or more for original approvals
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Trial duration of 12 months or more for supplemental approvals
Number of subjects: 181
Study: 32513229

Group type: EXPERIMENTAL
Intervention: Active peeling of the internal limiting membrane (ILM)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No peeling of the internal limiting membrane (ILM)
Number of subjects: 106
Study: 35048389

Group type: EXPERIMENTAL
Intervention: ELEVATE
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Couples Connecting Mindfully (CCM)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 929
Study: 32312139

Group type: EXPERIMENTAL
Intervention: Dressing removal at 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dressing removal at 48 hours
Number of subjects: 0
Study: 33602588

Group type: EXPERIMENTAL
Intervention: Long tourniquet (LT) time
Number of subjects: 100

Group type: COMPARATOR
Intervention: Short tourniquet (ST) time
Number of subjects: 100
Study: 36380971

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg tablets daily for four weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg tablets twice daily for four weeks
Number of subjects: 90
Study: 32895855

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36161108

Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus caloric restriction
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Mediterranean diet alone
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control
Number of subjects: 185
Study: 36032439

Group type: EXPERIMENTAL
Intervention: Mechanical vestibular stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional balance exercises
Number of subjects: 30
Study: 35766956

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lidocaine plus Dexmedetomidine (Lidocaine: 1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion; Dexmedetomidine: 0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 160
Study: 33773628

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33833179

Group type: EXPERIMENTAL
Intervention: Vibration analgesia using the Buzzy device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (propofol infusion without vibration analgesia)
Number of subjects: 100
Study: 34972028

Group type: EXPERIMENTAL
Intervention: Contact-based video (IG-1, n = 222)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Contact-based video plus psychoeducational video (IG-2, n = 216)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group (CG, n = 188)
Number of subjects: 626
Study: 33667587

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (CRT)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Adjuvant gemcitabine alone
Number of subjects: 111
Study: 35944270

Group type: EXPERIMENTAL
Intervention: Gamification program with mobile app
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 32997437

Group type: EXPERIMENTAL
Intervention: Oscillatory positive expiratory pressure therapy (OPEPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional chest physiotherapy (CCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OPEPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCP
Number of subjects: 0
Study: 35190420

Group type: EXPERIMENTAL
Intervention: 'Is insulin right for me?' (intervention)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Widely available online resources (control)
Number of subjects: 392
Study: 32691639

Group type: EXPERIMENTAL
Intervention: Dichrostachys glomerata (DG; 300 mg/d)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dichrostachys glomerata with caffeine (DG + C)
Number of subjects: 68
Study: 33035472

Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study: 616500056

Group type: EXPERIMENTAL
Intervention: Monitored group
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 35577699

Group type: EXPERIMENTAL
Intervention: Radiomics features based on lung CT using supervised machine learning
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: SVM model for two-class differentiation
Number of subjects: 252
Study: 33590342

Group type: EXPERIMENTAL
Intervention: Beach tennis session
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control session (seated rest)
Number of subjects: 24
Study: 35704218

Group type: EXPERIMENTAL
Intervention: Intravenous calcium gluconate (IV) 10% (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral elemental calcium (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous calcium gluconate (IV) 10%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral elemental calcium
Number of subjects: 60
Study: 33427749

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CD8+ T cell responses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific T cells
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T cell differentiation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immune response modeling
Number of subjects: 30
Study: 33455112

Group type: EXPERIMENTAL
Intervention: FLOT neoadjuvant chemotherapy with omega 3
Number of subjects: 42

Group type: COMPARATOR
Intervention: FLOT chemotherapy alone
Number of subjects: 42
Study: 36105936

Group type: EXPERIMENTAL
Intervention: Stent combined with laparoscopic therapeutic based on ERAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stent combined with laparoscopic therapeutic
Number of subjects: 60
Study: 33977587

Group type: EXPERIMENTAL
Intervention: Home physical exercise and sleep hygiene
Number of subjects: 125
Study: 32453377

Group type: EXPERIMENTAL
Intervention: Viltolarsen 40 mg/kg per week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg per week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (natural history controls)
Number of subjects: 16
Study: 35108294

Group type: EXPERIMENTAL
Intervention: Substance use preventive intervention arm (short handbook, two meetings with interventionist, two SMS messages per week)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Attention-control condition (same dose as intervention but focused on nutrition, physical activity, and weight stigma)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Substance use preventive intervention arm
Number of subjects: 500
Study: 32991907

Group type: EXPERIMENTAL
Intervention: Machine learning/image recognition model trained with 627 images
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Machine learning/image recognition model trained with 1169 images
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Inter-rater analysis among expert pediatric urologists
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Intra-rater analysis among expert pediatric urologists
Number of subjects: 1169
Study: 35529427

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) and Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (microfracture only)
Number of subjects: 38
Study: 33326576

Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 2153
Study: 36049266

Group type: EXPERIMENTAL
Intervention: Sensorimotor insoles (N=28)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Supporting insoles (N=23)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo insoles (N=22)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (Placebo insoles)
Number of subjects: 73
Study: 34148181

Group type: EXPERIMENTAL
Intervention: Structured chaplain intervention (12 sessions of 50 minutes each)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 35860417

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham electro-acupuncture (SA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Amitriptyline (medication group)
Number of subjects: 84
Study: 35385934

Group type: EXPERIMENTAL
Intervention: LPS+HDM
Number of subjects: 6

Group type: COMPARATOR
Intervention: PBS+HDM
Number of subjects: 6

Group type: COMPARATOR
Intervention: PBS+PBS
Number of subjects: 6
Study: 33096556

Group type: EXPERIMENTAL
Intervention: IgA concentration
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Lactoferrin concentration
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Lactalbumin concentration
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Absolute abundance of HMOs (among secretors)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Relative abundance of fucosylated HMOs (among secretors)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Relative abundance of sialylated HMOs (among secretors)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Osteopontin concentration (among secretors)
Number of subjects: 659
Study: 36374502

Group type: EXPERIMENTAL
Intervention: CO‐IMPACT intervention
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 239
Study: 35132039

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment targeting SBP of less than 120 mmHg
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure treatment targeting SBP of less than 140 mmHg
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361
Study: 32341044

Group type: EXPERIMENTAL
Intervention: Lower extremity nerve decompression surgery (LEND)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Conventional non-surgical care
Number of subjects: 344
Study: 36256688

Group type: EXPERIMENTAL
Intervention: VR-SH (superhero avatar)
Number of subjects: 30

Group type: COMPARATOR
Intervention: VR-Play (neutral avatar)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (VR-SH and VR-Play)
Number of subjects: 30
Study: 33873028

Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Treatment-Control (TCC)
Number of subjects: 118
Study: 34653660

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg in addition to standard therapeutic care)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (standard therapeutic care only)
Number of subjects: 158
Study: 34407343

Group type: EXPERIMENTAL
Intervention: 10 mg atogepant
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: 30 mg atogepant
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: 60 mg atogepant
Number of subjects: 873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 873
Study: 33216398

Group type: EXPERIMENTAL
Intervention: Positively framed films in VR
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Positively framed films in 2D
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Fear appeal films in VR
Number of subjects: 146

Group type: COMPARATOR
Intervention: Fear appeal films in 2D
Number of subjects: 146
Study: 32246706

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 195
Study: 33307409

Group type: EXPERIMENTAL
Intervention: Tuned Random Forest (RF) model with 300 iterations and 10 variables
Number of subjects: 42257

Group type: COMPARATOR
Intervention: Multinomial Logistic Regression (MLR) model
Number of subjects: 42257

Group type: EXPERIMENTAL
Intervention: Tuned Random Forest (RF) model
Number of subjects: 42257
Study: 33037961

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (GCBT) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 36229981

Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF) for 12 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 25
Study: 33830064

Group type: EXPERIMENTAL
Intervention: Step Away mobile app
Number of subjects: 55
Study: 35253564

Group type: EXPERIMENTAL
Intervention: Wrist‐ankle acupuncture
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (false acupuncture)
Number of subjects: 200
Study: 35094848

Group type: EXPERIMENTAL
Intervention: fevipiprant 150 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: fevipiprant 450 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 32652205

Group type: EXPERIMENTAL
Intervention: Near visual acuity (VA)
Number of subjects: 6851

Group type: EXPERIMENTAL
Intervention: Distance visual acuity (VA)
Number of subjects: 6851

Group type: COMPARATOR
Intervention: Overall eyesight subscale scores
Number of subjects: 6851

Group type: COMPARATOR
Intervention: Difficulty in activities scores
Number of subjects: 6851

Group type: COMPARATOR
Intervention: Social functioning scores
Number of subjects: 6851
Study: 32297992

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35250344

Group type: EXPERIMENTAL
Intervention: Cooling trial (ice-cold towels on forehead and neck for 3 min during offensive half innings)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control trial (no cooling intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cooling trial
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cooling trial and Control trial
Number of subjects: 10
Study: 32006699

Group type: EXPERIMENTAL
Intervention: Levorphanol (potent opioid), average final daily dose 132 mg (range 14 to 300 mg), with 5 weeks titration followed by 20 weeks stable dosing.
Number of subjects: 30
Study: 34018365

Group type: EXPERIMENTAL
Intervention: Hyperin treatment at 75 mg/(kg·d) for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: POI model group (TG at 40 mg/kg twice a day for 2 weeks)
Number of subjects: 120
Study: 34914418

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention (n = 55)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attentional control condition (n = 45)
Number of subjects: 100
Study: 34177646

Group type: EXPERIMENTAL
Intervention: Tai Chi training (3 sessions of 60 minutes per week for 12 weeks)
Number of subjects: 76
Study: 32777010

Group type: EXPERIMENTAL
Intervention: Elevated amyloid levels
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Not elevated amyloid levels
Number of subjects: 1705
Study: 36164417

Group type: EXPERIMENTAL
Intervention: Quality Control Circle Activity Care (QCCAC)
Number of subjects: 119
Study: 33709808

Group type: EXPERIMENTAL
Intervention: Perceived discrimination due to race
Number of subjects: 0
Study: 35988261

Group type: EXPERIMENTAL
Intervention: Soft-voting classifier using SVM, LR, and KNN
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Machine learning classification models (RF, XGBoost, SVM, LR, KNN)
Number of subjects: 101
Study: 32434666

Group type: EXPERIMENTAL
Intervention: HeatTens (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study: 32714989

Group type: EXPERIMENTAL
Intervention: Jaques-Dalcroze Eurhythmics exercise programme (12 weeks, twice a week for 45 minutes)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 73
Study: 35476094

Group type: EXPERIMENTAL
Intervention: Multiprofessional remote intervention with a nurse for 16 weeks via a messaging application
Number of subjects: 0